Tuesday, 27 September 2016

Ramelteon


Class: Anxiolytics, Sedatives, and Hypnotics; Miscellaneous
VA Class: CN300
Chemical Name: N-[2-[8S)-1,6,7,8-Tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl-propanamide
Molecular Formula: C16H21NO2
CAS Number: 196597-26-9
Brands: Rozerem


REMS:


FDA approved a REMS for ramelteon to ensure that the benefits of a drug outweigh the risks. However, FDA later rescinded REMS requirements. See the FDA REMS page () or the ASHP REMS Resource Center ().



Introduction

Melatonin receptor agonist; hypnotic.1 2


Uses for Ramelteon


Insomnia


Management of insomnia characterized by difficulty with sleep onset.1


Decreases sleep latency in patients with transient insomnia.1 2 Decreases sleep latency in patients with chronic insomnia receiving therapy for up to 35 days.1 2 3 4 5


Ramelteon Dosage and Administration


Administration


Oral Administration


Administer orally within 30 minutes of bedtime.1 2


Avoid administration with or immediately after a high-fat meal because of potentially decreased rate of absorption.1 2 (See Food under Pharmacokinetics.)


Dosage


Adults


Insomnia

Oral

8 mg.1 2


Special Populations


Hepatic Impairment


Increased exposure to drug and active metabolite.1 (See Special Populations under Pharmacokinetics.) No specific dosage recommendations at this time.1 However, use with caution in patients with moderate hepatic impairment; avoid use in patients with severe hepatic impairment.1


Renal Impairment


No dosage adjustment necessary in patients with mild, moderate, or severe renal impairment or in those requiring chronic hemodialysis.1


Cautions for Ramelteon


Contraindications



  • Hypersensitivity to ramelteon or any ingredient in the formulation.1



Warnings/Precautions


Warnings


Adequate Patient Evaluation

Sleep disturbances may be a manifestation of a physical and/or psychiatric disorder; carefully evaluate patient before providing symptomatic treatment.1


Failure of insomnia to remit after a reasonable treatment period, exacerbation of insomnia, and/or emergence of new cognitive or behavioral abnormalities may indicate the presence of an underlying psychiatric or physical disorder requiring further patient evaluation.1


Complex Sleep-related Behaviors

Potential risk of complex sleep-related behaviors such as sleep-driving (i.e., driving while not fully awake after ingesting a sedative-hypnotic drug, with no memory of the event), making phone calls, or preparing and eating food while asleep.6


Sensitivity Reactions


Potential risk of anaphylaxis and angioedema; may occur as early as with the first dose of drug.6


Major Toxicities


Psychiatric Effects

Cognitive and behavioral changes reported.1 In primarily depressed patients, exacerbation of depression and suicidal ideation reported following use of hypnotics.1


Immediately evaluate any new psychiatric abnormalities.1


Endocrine Effects

Increased prolactin concentrations reported in patients with chronic insomnia receiving ramelteon 16 mg daily for 6 months.1


Abnormal morning cortisol concentrations (resulting in abnormal corticotropin [ACTH] stimulation test results) reported in 2 patients and prolactinoma reported in 1 patient receiving long-term (up to 12 months) therapy; causal relationship to drug not established.1


If unexplained amenorrhea, galactorrhea, decreased libido, or fertility problems occur, consider evaluating prolactin or testosterone concentrations.1


Abuse Potential and Dependence

No evidence of abuse potential detected following administration of doses up to 20 times the recommended hypnotic dose in patients with a history of drug abuse or dependence.1 2


No evidence of physical dependence.1


Withdrawal

No evidence of a withdrawal syndrome, including rebound insomnia, following discontinuance of long-term therapy (4, 8, or 16 mg daily for up to 35 days).1 2


Residual Effects

Next-day residual effects (reduced immediate/delayed memory recall and increased sluggishness, fatigue, and irritation) detected at weeks 1 and 3 but not week 5 of therapy in adult patients receiving ramelteon 8 mg daily.1 2 Residual effects not detected in a similar study in geriatric patients receiving ramelteon 4 or 8 mg daily.1 2


General Precautions


Long-term Safety

No clinically meaningful changes in laboratory parameters, endocrine tests, vital signs, ECG recordings, or intensity of menstrual bleeding detected in patients with chronic insomnia following up to 1 year of therapy.2 Rebound insomnia not observed following 1 year of therapy.2


Concomitant Diseases

No respiratory depressant effect in patients with mild to moderate COPD.1 Effects in patients with severe COPD (e.g., those with elevated pCO2, those requiring nocturnal oxygen therapy) not studied; use in these patients not recommended.1


No differences in measures of apnea indices observed in patients with mild to moderate obstructive sleep apnea.1 Effects in patients with severe obstructive sleep apnea not studied; use in these patients not recommended.1


Specific Populations


Pregnancy

Category C.1


Lactation

Distributed into milk in rats; not known whether distributed into human milk.1 Use not recommended.1


Pediatric Use

Safety and efficacy not established in pediatric patients.1


Geriatric Use

Increased exposure to drug and active metabolite.1 (See Special Populations under Pharmacokinetics.) However, no overall differences in safety or efficacy relative to younger adults.1


Hepatic Impairment

Use with caution in patients with moderate hepatic impairment; avoid use in patients with severe hepatic impairment.1 (See Special Populations under Pharmacokinetics.)


Common Adverse Effects


Headache, somnolence, dizziness, fatigue, nausea, exacerbation of insomnia, upper respiratory tract infection, diarrhea, myalgia, depression, dysgeusia, arthralgia.1


Interactions for Ramelteon


Metabolized principally by CYP1A2 and, to a lesser extent, by the CYP2C subfamily and by CYP3A4.1


Drugs Affecting Hepatic Microsomal Enzymes


Inhibitors of CYP1A2: Potential pharmacokinetic interaction (substantially increased serum ramelteon concentrations).1 Avoid concomitant use with strong CYP1A2 inhibitors; caution if used concomitantly with less potent CYP1A2 inhibitors.1


Inhibitors of CYP3A4 and CYP2C9: Potential pharmacokinetic interaction (increased serum concentrations of ramelteon and active metabolite).1 Caution if used concomitantly with potent inhibitors of CYP3A4 or CYP2C9.1


Inducers of CYP isoenzymes: Potential pharmacokinetic interaction (decreased serum concentrations of ramelteon and active metabolite).1 Possibly reduced ramelteon efficacy when used concomitantly with potent CYP inducers.1 2


Drugs Metabolized by Hepatic Microsomal Enzymes


Substrates of CYP isoenzymes 1A2, 2C9, 2C19, 2D6, and 3A4: Pharmacokinetic interaction unlikely.1


Specific Drugs













































Drug or Test



Interaction



Comments



Alcohol



Additive sedative effects1



Avoid concomitant use1



Dextromethorphan



Pharmacokinetic interaction unlikely1



Digoxin



Pharmacokinetic interaction unlikely1



Fluconazole



Increased peak serum concentrations and AUC of ramelteon and active metabolite1



Use concomitantly with caution1



Fluoxetine



Pharmacokinetic interaction unlikely1



Fluvoxamine



Substantially increased peak serum concentration and AUC of ramelteon1



Avoid concomitant use1



Ketoconazole



Increased peak serum concentration and AUC of ramelteon and active metabolite1



Use concomitantly with caution1



Midazolam



Pharmacokinetic interaction unlikely1



Omeprazole



Pharmacokinetic interaction unlikely1



Rifampin



Decreased peak serum concentration and AUC of ramelteon and active metabolite1



Concomitant use may reduce efficacy of ramelteon1 2



Theophylline



Pharmacokinetic interaction unlikely1



Warfarin



Pharmacokinetic interaction unlikely1



Urine Drug Screening



No false-positive results for urine drug screening of benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines1


Ramelteon Pharmacokinetics


Absorption


Bioavailability


Rapidly absorbed; following oral administration in fasting state, peak serum concentrations occur at approximately 0.75 hour.1


Total absorption is ≥84%; however, absolute oral bioavailability is 1.8% because of extensive first-pass metabolism.1


Food


High-fat meal delays time to peak serum concentration by 45 minutes, reduces peak serum concentration by 22%, and increases AUC by 31%.1 (See Oral Administration under Dosage and Administration.)


Special Populations


In geriatric patients, peak serum concentrations and AUC of ramelteon are increased by 86 and 97%, respectively.1 Peak serum concentrations and AUC of active metabolite also are increased, but to a lesser extent.1


In patients with mild or moderate hepatic impairment, exposure to ramelteon is increased 4- or 10-fold, respectively.1 Exposure to active metabolite is marginally increased.1 Pharmacokinetic parameters not evaluated in patients with severe hepatic impairment (Child-Pugh class C).1 (See Hepatic Impairment under Cautions.)


Pharmacokinetic parameters not altered in patients with renal impairment or in those requiring chronic hemodialysis.1


Distribution


Extent


Extensively distributed into tissues; not distributed selectively to red blood cells.1


Plasma Protein Binding


Approximately 82% (mainly [70%] albumin).1


Elimination


Metabolism


Metabolized principally by CYP1A2 and, to a lesser extent, by the CYP2C subfamily and by CYP3A4 to active (M-II) and inactive metabolites.1


Elimination Route


Excreted in urine (84%) and feces (4%), principally as metabolites.1


Half-life


1–2.6 hours (for ramelteon) and 2–5 hours (for active metabolite).1


Stability


Storage


Oral


Capsules

Tightly-closed containers at 25°C (may be exposed to 15–30°C).1 Protect from moisture and humidity.1


Actions



  • Exhibits high affinity for melatonin MT1 and MT2 receptors.1 2 Agonist activity at these receptors may contribute to the drug’s sleep-inducing properties.1 2




  • Demonstrates lower selectivity for melatonin MT3 receptors than for MT1 and MT2 receptors.1 Has no appreciable affinity for the GABA receptor complex or for receptors that bind neuropeptides, cytokines, serotonin, dopamine, norepinephrine, acetylcholine, or opiates.1



Advice to Patients



  • Necessity of administering within 30 minutes of bedtime and limiting activities to only those necessary to prepare for bed.1 Avoid administration with or immediately after a high-fat meal.1




  • Necessity of avoiding driving, operating machinery, or performing hazardous tasks following administration.1 Importance of avoiding alcohol during therapy.1




  • Importance of consulting a clinician if worsening insomnia or emergence of new behavioral manifestations occurs.1




  • Importance of consulting a clinician if cessation of menses or galactorrhea (in women), decreased libido, or problems with fertility occur.1




  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1




  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.1




  • Importance of informing patients of other important precautionary information.1 (See Cautions.)



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.













Ramelteon

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Tablets, film-coated



8 mg



Rozerem



Takeda


Comparative Pricing


This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 10/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.


Rozerem 8MG Tablets (TAKEDA PHARMACEUTICALS): 30/$171.00 or 90/$472.99



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions October 27, 2011. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.




References



1. Takeda Pharmaceuticals America, Inc. Rozerem (ramelteon) tablets prescribing information. Lincolnshire, IL; 2005 Aug.



2. Takeda Pharmaceuticals America, Inc., Lincolnshire, IL: Personal communication.



3. Zammit G, Roth T, Erman M et al. Double-blind, placebo-controlled polysomnography and outpatient trial to evaluate the efficacy and safety of ramelteon in adult patients with chronic insomnia. Sleep. 2005; 28(Suppl):A228-9.



4. Roth T, Seiden D, Weigand S et al. Phase III study to determine the efficacy of ramelteon in elderly patients with chronic insomnia. Proceedings of New Clinical Drug Evaluation Unit. June 6-9, 2005, Boca Raton, Fla. Poster abstract.



5. Roth T, Seiden D, Zee P et al. Phase III outpatient trial of ramelteon for the treatment of chronic insomnia in elderly patients. J Am Geriatr Soc. 2005; 53(Suppl):S25. Abstract.



6. Food and Drug Administration. Rozerem (ramelteon) tablets. [March 14, 2007: Takeda] MedWatch drug labeling changes. Rockville, MD; April 2007. From FDA websites () and ().



More Ramelteon resources


  • Ramelteon Side Effects (in more detail)
  • Ramelteon Use in Pregnancy & Breastfeeding
  • Ramelteon Drug Interactions
  • Ramelteon Support Group
  • 29 Reviews for Ramelteon - Add your own review/rating


  • Ramelteon MedFacts Consumer Leaflet (Wolters Kluwer)

  • Ramelteon Professional Patient Advice (Wolters Kluwer)

  • ramelteon Advanced Consumer (Micromedex) - Includes Dosage Information

  • Rozerem Prescribing Information (FDA)

  • Rozerem Consumer Overview



Compare Ramelteon with other medications


  • Insomnia

Monday, 26 September 2016

Menotropins




In the US, Menotropins (menotropins systemic) is a member of the drug class gonadotropins and is used to treat Female Infertility, Follicle Stimulation and Ovulation Induction.

US matches:

  • Menotropins

  • Menotropins injectable

Scheme

USAN

CAS registry number (Chemical Abstracts Service)

0009002-68-0

Therapeutic Category

Pituitary gonadotropin

Foreign Names

  • Menotropin (German)
  • Ménotropine (French)

Generic Names

  • Gonadotropine hypophysaire (OS: DCF)
  • Menotrophin (OS: BAN)
  • Ménotropine (OS: DCF)
  • Menotropins (OS: USAN)
  • Gonadotrophine hypophysaire (IS: DCF vieille)
  • Gonadotropinum hypophysicum (IS)
  • HMG (IS)
  • HPMG (IS)
  • Human Menopausal Gonadotrophins (IS)
  • Urogonadotropin (IS)
  • Menotrophin (PH: BP 2010)
  • Menotropina (PH: F.U. IX)
  • Menotropins (PH: USP 32)

Brand Names

  • Fertinorm P
    Merck Serono, Japan


  • Folyrmon P
    Fuji Yakuhin, Japan


  • Gonadoryl
    Mochida, Japan


  • Gonapure
    ASKA SeiyakuAsuka, Japan


  • HMG Lepori
    Farma Lepori, Spain


  • HMG Massone
    Quality, Peru


  • HMG
    ASKA SeiyakuAsuka, Japan; Fuji Yakuhin, Japan; Nikken, Japan


  • Humegon
    Organon, United Arab Emirates; Organon, Bahrain; Organon, Cyprus; Organon, Egypt; Organon, Ghana; Organon, Ireland; Organon, Iraq; Organon, Iran; Organon, Jordan; Organon, Japan; Organon, Kenya; Organon, Kuwait; Organon, Lebanon; Organon, Sri Lanka; Organon, Luxembourg; Organon, Libya; Organon, Qatar; Organon, Saudi Arabia; Organon, Sudan; Organon, Syria; Organon, Tanzania; Organon, Yemen; Organon, Zambia; Organon, Zimbabwe


  • Humog
    GP Pharm, Peru


  • Menogon
    Ferring, United Arab Emirates; Ferring, Bahrain; Ferring, Czech Republic; Ferring, Germany; Ferring, Egypt; Ferring, Greece; Ferring, Hong Kong; Ferring, Israel; Ferring, Italy; Ferring, Jordan; Ferring, Kuwait; Ferring, Lebanon; Ferring, Oman; Ferring, Poland; Ferring, Qatar; Ferring, Romania; Ferring, Saudi Arabia; Ferring, Singapore; Ferring, Syria; Ferring, Thailand; Ferring, Turkey; Ferring, Yemen


  • Menopur
    ARIS, Turkey; Dr. Fisher, Netherlands; EU-Pharma, Netherlands; Euro, Netherlands; Ferring, Argentina; Ferring, Austria; Ferring, Belgium; Ferring, Canada; Ferring, Switzerland; Ferring, Czech Republic; Ferring, Denmark; Ferring, Spain; Ferring, Finland; Ferring, France; Ferring, United Kingdom; Ferring, Greece; Ferring, Hong Kong; Ferring, Hungary; Ferring, Ireland; Ferring, Israel; Ferring, Iceland; Ferring, Luxembourg; Ferring, Luxembourg; Ferring, Netherlands; Ferring, Norway; Ferring, Oman; Ferring, Portugal; Ferring, Serbia; Ferring, Sweden; Ferring, Slovakia; Ferring, Tunisia; Ferring, Taiwan; Ferring, United States; Ferring, South Africa; Ferring Pharmaceuticals, Poland; PharmaSwiss, Croatia (Hrvatska); PharmaSwiss, Slovenia


  • Merapur
    Ferring, Mexico


  • Merional
    ARIS, Turkey; Faran Laboratories, Greece; IBSA, Switzerland; IBSA, Czech Republic; IBSA, Hungary; IBSA, Oman; IBSA, Serbia; IBSA, Slovakia; Pharmasure, United Kingdom


  • Meropur
    Ferring, Italy


  • Pergonal
    Serono, Luxembourg; Serono, Peru; Serono, Russian Federation; Serum Institute, India; Teva, Israel


  • Pregnorm
    Win-Medicare, India


  • Repronex
    Ferring, Canada; Ferring, United States

International Drug Name Search

Glossary

BANBritish Approved Name
DCFDénomination Commune Française
ISInofficial Synonym
OSOfficial Synonym
PHPharmacopoeia Name
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Trandolapril-DP




Trandolapril-DP may be available in the countries listed below.


Ingredient matches for Trandolapril-DP



Trandolapril

Trandolapril is reported as an ingredient of Trandolapril-DP in the following countries:


  • Australia

International Drug Name Search

Ronic




Ronic may be available in the countries listed below.


Ingredient matches for Ronic



Dexamethasone

Dexamethasone 21-(disodium phosphate) (a derivative of Dexamethasone) is reported as an ingredient of Ronic in the following countries:


  • Portugal

International Drug Name Search

Finol




Finol may be available in the countries listed below.


Ingredient matches for Finol



Finasteride

Finasteride is reported as an ingredient of Finol in the following countries:


  • Iceland

International Drug Name Search

Bisoblock




Bisoblock may be available in the countries listed below.


Ingredient matches for Bisoblock



Bisoprolol

Bisoprolol fumarate (a derivative of Bisoprolol) is reported as an ingredient of Bisoblock in the following countries:


  • Hungary

  • Latvia

  • Lithuania

  • Poland

  • Slovenia

International Drug Name Search

Mylotarg


Pronunciation: gem-TOO-zoo-mab oh-zoh-ga-MYE-sin
Generic Name: Gemtuzumab Ozogamicin
Brand Name: Mylotarg

Mylotarg should not be used along with other chemotherapy medicines. Severe bone marrow problems occur even at normal doses of Mylotarg. Severe and sometimes fatal allergic reactions and lung problems have occurred with use of Mylotarg. Tell the doctor immediately if you experience rash; hives; difficulty breathing; swelling of the mouth, face, lips, or tongue; or severe dizziness. Mylotarg may also increase the risk of severe and sometimes fatal liver problems. This risk may be increased if you have liver problems, you have had a hematopoietic stem-cell transplant (HSCT), or you use Mylotarg in combination with other chemotherapy medicines. Contact your doctor immediately if you experience sudden weight gain, right-sided stomach pain, stomach swelling, yellowing of the eyes or skin, or dark urine. Your doctor will monitor you closely while you use Mylotarg.





Mylotarg is used for:

Treating acute myeloid leukemia (AML) in patients 60 years of age and older who cannot take other cancer medications. It may also be used for other conditions as determined by your doctor.


Mylotarg is a chemotherapy agent. It works by binding to and breaking specific parts that the cancer cell needs to survive.


Do NOT use Mylotarg if:


  • you are allergic to any ingredient in Mylotarg

Contact your doctor or health care provider right away if any of these apply to you.



Before using Mylotarg:


Some medical conditions may interact with Mylotarg. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, plan to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have liver or kidney problems or lung disease

Some MEDICINES MAY INTERACT with Mylotarg. However, no specific interactions with Mylotarg are known at this time.


This may not be a complete list of all interactions that may occur. Ask your health care provider if Mylotarg may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Mylotarg:


Use Mylotarg as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Mylotarg is usually administered as an infusion at your doctor's office, hospital, or clinic. If you are using Mylotarg at home, carefully follow the infusion procedures taught to you by your health care provider.

  • You may need to take certain other medicines (eg, acetaminophen, diphenhydramine) before using Mylotarg in order to help decrease the risk of certain side effects that may occur while using Mylotarg. Discuss any questions or concerns with your doctor.

  • If Mylotarg contains particles or is discolored, or if the vial is cracked or damaged in any way, do not use it.

  • Keep this product, as well as syringes and needles, out of the reach of children. Do not reuse needles, syringes, or other materials. Dispose of properly after use. Ask your doctor or pharmacist to explain local regulations for proper disposal.

  • If you miss a dose of Mylotarg, or your dose is interrupted, contact your doctor immediately.

Ask your health care provider any questions you may have about how to use Mylotarg.



Important safety information:


  • Mylotarg may cause dizziness. Do not drive, operate machinery, or do anything else that could be dangerous until you know how you react to Mylotarg. Using Mylotarg alone, with certain other medicines, or with alcohol may lessen your ability to drive or perform other potentially dangerous tasks.

  • Mylotarg may reduce the number of clot-forming cells (platelets) in your blood. To prevent bleeding, avoid situations in which bruising or injury may occur. Report any unusual bleeding, bruising, blood in stools, or dark, tarry stools to your doctor.

  • Mylotarg may lower your body's ability to fight infection. Prevent infection by avoiding contact with people with colds or other infections. Notify your doctor of any signs of infection, including fever, sore throat, rashes, or chills.

  • LAB TESTS, including liver function tests, complete blood cell counts, platelet counts, and electrolytes, may be performed to monitor your progress or to check for side effects. Be sure to keep all doctor and lab appointments.

  • Use Mylotarg with extreme caution in CHILDREN. Safety and effectiveness have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: Mylotarg may cause harm to the fetus. Avoid becoming pregnant while you are using Mylotarg. If you think you may become pregnant, discuss with your doctor the benefits and risks of using Mylotarg during pregnancy. It is unknown if Mylotarg is excreted in breast milk. Do not breast-feed while taking Mylotarg.


Possible side effects of Mylotarg:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Back pain; constipation; cough; diarrhea; dizziness; fatigue; headache; indigestion; joint pain; loss of appetite; mouth sores; nausea; pain or inflammation at the injection site; runny nose; sleeplessness; stomach pain; vomiting; weakness.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); change in amount or frequency of urine; chest pain; dark urine; depression; fast or irregular heart rate; fever, chills, or sore throat; increased thirst; one-sided weakness; pink or red-colored urine; right-sided stomach pain; seizure; severe dizziness; severe headache; shortness of breath; slurred speech; stomach swelling; sudden weight gain; swelling of the arms, legs, or feet; unusual bleeding or bruising (eg, nosebleed, red or purple spots under the skin, unusual vaginal bleeding); vision changes; yellowing of the eyes or skin.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Mylotarg side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.


Proper storage of Mylotarg:

Mylotarg is usually handled and stored by a health care provider. If you are using Mylotarg at home, store Mylotarg as directed by your pharmacist or health care provider.


General information:


  • If you have any questions about Mylotarg, please talk with your doctor, pharmacist, or other health care provider.

  • Mylotarg is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Mylotarg. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Mylotarg resources


  • Mylotarg Side Effects (in more detail)
  • Mylotarg Use in Pregnancy & Breastfeeding
  • Mylotarg Drug Interactions
  • Mylotarg Support Group
  • 0 Reviews for Mylotarg - Add your own review/rating


  • Mylotarg Prescribing Information (FDA)

  • Mylotarg Concise Consumer Information (Cerner Multum)

  • Mylotarg Monograph (AHFS DI)

  • Mylotarg Advanced Consumer (Micromedex) - Includes Dosage Information



Compare Mylotarg with other medications


  • Acute Myeloid Leukemia